

Pål Johansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4815966/publications.pdf>

Version: 2024-02-01

103
papers

5,412
citations

87888

38
h-index

85541

71
g-index

111
all docs

111
docs citations

111
times ranked

5858
citing authors

#	ARTICLE	IF	CITATIONS
1	Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17908-17912.	7.1	308
2	Formulation aspects of biodegradable polymeric microspheres for antigen delivery. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 357-376.	13.7	299
3	Immunity in response to particulate antigen-delivery systems. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 333-355.	13.7	277
4	Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1290-1296.	2.9	236
5	Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2000, 50, 129-146.	4.3	207
6	Use of Aâ€¢type CpG oligodeoxynucleotides as an adjuvant in allergenâ€¢specific immunotherapy in humans: a phase I/IIa clinical trial. <i>Clinical and Experimental Allergy</i> , 2009, 39, 562-570.	2.9	194
7	Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. <i>Journal of Controlled Release</i> , 2010, 147, 342-349.	9.9	194
8	Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 997-1002.	2.9	180
9	Inflammasome activation and IL-1Î² target IL-1Î± for secretion as opposed to surface expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18055-18060.	7.1	166
10	Antigen kinetics determines immune reactivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5189-5194.	7.1	158
11	Epicutaneous allergen-specific immunotherapy ameliorates grass pollenâ€¢induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 128-135.	2.9	148
12	Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. <i>Pharmaceutical Research</i> , 1998, 15, 1103-1110.	3.5	141
13	Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. <i>Blood</i> , 2009, 113, 377-388.	1.4	126
14	Direct intralymphatic injection of peptide vaccines enhances immunogenicity. <i>European Journal of Immunology</i> , 2005, 35, 568-574.	2.9	105
15	A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-Î± Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis. <i>Journal of Immunology</i> , 2007, 178, 7450-7457.	0.8	104
16	Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2009, 150, 59-65.	2.1	98
17	Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 707-710.	5.7	76
18	Intralymphatic immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 537-543.	2.3	75

#	ARTICLE	IF	CITATIONS
19	Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. <i>European Journal of Immunology</i> , 2005, 35, 1869-1876.	2.9	70
20	Histamine H1 Receptor Promotes Atherosclerotic Lesion Formation by Increasing Vascular Permeability for Low-Density Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 923-930.	2.4	67
21	Thermodynamic approach to protein microencapsulation into poly(D,L-lactide) by spray drying. <i>International Journal of Pharmaceutics</i> , 1996, 129, 51-61.	5.2	63
22	Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs. <i>Vaccine</i> , 1999, 18, 209-215.	3.8	62
23	Technological considerations related to the up-scaling of protein microencapsulation by spray-drying. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2000, 50, 413-417.	4.3	62
24	A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles. <i>Pharmaceutical Research</i> , 2007, 24, 1927-1935.	3.5	61
25	Lympho-geographical concepts in vaccine delivery. <i>Journal of Controlled Release</i> , 2010, 148, 56-62.	9.9	61
26	Semi-permeable coatings fabricated from comb-polymers efficiently protect proteins in vivo. <i>Nature Communications</i> , 2014, 5, 5526.	12.8	61
27	Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1591-1598.	2.9	57
28	Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. <i>Journal of Controlled Release</i> , 2008, 130, 161-167.	9.9	57
29	Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. <i>Vaccine</i> , 2000, 19, 1047-1054.	3.8	54
30	Relief from Zmp1-Mediated Arrest of Phagosome Maturation Is Associated with Facilitated Presentation and Enhanced Immunogenicity of Mycobacterial Antigens. <i>Vaccine Journal</i> , 2011, 18, 907-913.	3.1	54
31	Blocking IL-1 β but not IL-1 γ increases susceptibility to chronic <i>Mycobacterium tuberculosis</i> infection in mice. <i>Vaccine</i> , 2011, 29, 1339-1346.	3.8	53
32	Coated Textiles in the Treatment of Atopic Dermatitis. , 2006, 33, 144-151.		49
33	Antimicrobial Silk Clothing in the Treatment of Atopic Dermatitis Proves Comparable to Topical Corticosteroid Treatment. <i>Dermatology</i> , 2006, 213, 228-233.	2.1	49
34	Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents. <i>Pharmaceutical Research</i> , 1998, 15, 1111-1116.	3.5	48
35	Preclinical efficacy and safety of an anti-IL-1 β vaccine for the treatment of type 2 diabetes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14048.	4.1	47
36	Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. <i>European Journal of Immunology</i> , 2005, 35, 3591-3598.	2.9	46

#	ARTICLE	IF	CITATIONS
37	Deletion of <i>zmp1</i> improves <i>Mycobacterium bovis</i> BCG-mediated protection in a guinea pig model of tuberculosis. <i>Vaccine</i> , 2015, 33, 1353-1359.	3.8	45
38	Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 172-178.	5.7	44
39	Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. <i>Expert Review of Vaccines</i> , 2007, 6, 471-474.	4.4	43
40	Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 965-967.e4.	2.9	40
41	Intralymphatic immunotherapy: Time interval between injections is essential. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 930-931.	2.9	40
42	Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 1999, 47, 193-201.	4.3	39
43	TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. <i>Blood</i> , 2013, 121, 85-94.	1.4	39
44	Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling. <i>Journal of Immunology</i> , 2018, 200, 3151-3159.	0.8	39
45	BATF3-dependent dendritic cells drive both effector and regulatory T-cell responses in bacterially infected tissues. <i>PLoS Pathogens</i> , 2019, 15, e1007866.	4.7	38
46	Ambiguities in the preclinical quality assessment of microparticulate vaccines. <i>Trends in Biotechnology</i> , 2000, 18, 203-211.	9.3	37
47	On technological and immunological benefits of multivalent single-injection microsphere vaccines. <i>Pharmaceutical Research</i> , 2002, 19, 1330-1336.	3.5	37
48	Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells. <i>Journal of Controlled Release</i> , 2015, 198, 10-17.	9.9	35
49	Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen. <i>Journal of Controlled Release</i> , 2014, 174, 143-150.	9.9	34
50	Physico-chemical and antigenic properties of tetanus and diphtheria toxoids and steps towards improved stability. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998, 1425, 425-436.	2.4	33
51	An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 957-966.	3.3	31
52	Intralymphatic Immunotherapy: From the Rationale to Human Applications. <i>Current Topics in Microbiology and Immunology</i> , 2011, 352, 71-84.	1.1	31
53	Release of tetanus toxoid from adjuvants and PLGA microspheres: How experimental set-up and surface adsorption fool the pattern. <i>Journal of Controlled Release</i> , 1998, 56, 209-217.	9.9	29
54	CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells. <i>European Journal of Immunology</i> , 2004, 34, 91-97.	2.9	29

#	ARTICLE	IF	CITATIONS
55	New routes for allergen immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1525-1533.	3.3	29
56	Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines. <i>Cancers</i> , 2020, 12, 165.	3.7	29
57	Anti-mycobacterial immunity induced by a single injection of <i>M. leprae</i> Hsp65-encoding plasmid DNA in biodegradable microparticles. <i>Immunology Letters</i> , 2003, 90, 81-85.	2.5	26
58	Functional differences between protamine preparations for the transfection of mRNA. <i>Drug Delivery</i> , 2020, 27, 1231-1235.	5.7	26
59	IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant <i>scp>MAT</scp>â€Feld1</i> in human. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1366-1370.	5.7	25
60	Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes. <i>Molecular Pharmaceutics</i> , 2016, 13, 320-329.	4.6	25
61	A Comparative Study of Real-Time RT-PCRâ€Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 796-804.	2.8	24
62	Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. <i>Journal of Controlled Release</i> , 2004, 99, 345-355.	9.9	23
63	Analysis of the Relationship between Pollinosis and Date of Birth in Switzerland. <i>International Archives of Allergy and Immunology</i> , 2007, 143, 269-275.	2.1	22
64	Photosensitizer and Light Pave the Way for Cytosolic Targeting and Generation of Cytosolic CD8 T Cells Using PLGA Vaccine Particles. <i>Journal of Immunology</i> , 2015, 195, 166-173.	0.8	22
65	Risk Assessment of Hymenoptera Re-Sting Frequency: Implications for Decision-Making in Venom Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 86-92.	2.1	20
66	Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 34-41.	4.3	20
67	Distinct T helper cell dependence of memory Bâ€cell proliferation versus plasma cell differentiation. <i>Immunology</i> , 2017, 150, 329-342.	4.4	20
68	Medication with antihistamines impairs allergenâ€specific immunotherapy in mice. <i>Clinical and Experimental Allergy</i> , 2008, 38, 512-519.	2.9	19
69	Encapsulation of antigen in poly(d,l-lactide-co-glycolide) microspheres protects from harmful effects of β -irradiation as assessed in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2012, 80, 274-281.	4.3	19
70	Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against <i>Mycobacterium tuberculosis</i> . <i>Vaccine</i> , 2013, 31, 1057-1064.	3.8	19
71	A dual role for hepatocyte-intrinsic canonical NF- κ B signaling in virus control. <i>Journal of Hepatology</i> , 2020, 72, 960-975.	3.7	18
72	Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinaseâ€dependent proinflammatory cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1286-1294.	2.9	17

#	ARTICLE	IF	CITATIONS
73	TLR4 as a negative regulator of keratinocyte proliferation. PLoS ONE, 2017, 12, e0185668.	2.5	17
74	Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine, 2006, 24, 1389-1394.	3.8	16
75	The antihistamines clemastine and desloratadine inhibit <sc>STAT</sc>3 and c&Myc activities and induce apoptosis in cutaneous T&cell lymphoma cell lines. Experimental Dermatology, 2013, 22, 119-124.	2.9	16
76	Cell-Specific Delivery Using an Engineered Protein Nanocage. ACS Chemical Biology, 2021, 16, 838-843.	3.4	16
77	The contact sensitizer diphenylcyclopropanone has adjuvant properties in mice and potential application in epicutaneous immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 638-646.	5.7	14
78	Efficacy and Safety of Allergen-Specific Immunotherapy in Rhinitis, Rhinoconjunctivitis, and Bee/Wasp Venom Allergies. International Reviews of Immunology, 2005, 24, 519-531.	3.3	13
79	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers, 2020, 12, 1694.	3.7	13
80	Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen. Clinical and Experimental Allergy, 2022, 52, 747-759.	2.9	13
81	Intralymphatic Immunotherapy and Vaccination in Mice. Journal of Visualized Experiments, 2014, , e51031.	0.3	12
82	Evaluation of visual analog scales for the assessment of symptom severity in allergic rhinoconjunctivitis. Annals of Allergy, Asthma and Immunology, 2007, 98, 134-138.	1.0	11
83	FBXO25 Promotes Cutaneous Squamous Cell Carcinoma Growth and Metastasis through Cyclin D1. Journal of Investigative Dermatology, 2020, 140, 2496-2504.	0.7	11
84	Photochemical internalization (PCI)-mediated activation of CD8 T cells involves antigen uptake and CCR7-mediated transport by migratory dendritic cells to draining lymph nodes. Journal of Controlled Release, 2021, 332, 96-108.	9.9	10
85	Immunotherapeutic Targeting of Allergic Disease. Inflammation and Allergy: Drug Targets, 2006, 5, 243-252.	1.8	9
86	Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help. Frontiers in Immunology, 2019, 10, 1548.	4.8	8
87	A Cutaneous Allergen Neutralisation Test That Correlates with the Duration of Venom Immunotherapy. International Archives of Allergy and Immunology, 2006, 141, 377-383.	2.1	5
88	Nickel sensitisation in mice: A critical appraisal. Journal of Dermatological Science, 2010, 58, 186-192.	1.9	5
89	Dosing intervals in intralymphatic immunotherapy. Clinical and Experimental Allergy, 2016, 46, 504-507.	2.9	5
90	Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans. Frontiers in Allergy, 2022, 3, 832010.	2.8	5

#	ARTICLE	IF	CITATIONS
91	Kinetics and persistence of antiâ€SARSâ€CoVâ€2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	2.7	5
92	Parenteral Vaccine Administration: Tried and True. <i>Advances in Delivery Science and Technology</i> , 2015, , 261-286.	0.4	4
93	Amphiphilic Cyclodextrinâ€Based Nanoparticulate Vaccines Can Trigger Tâ€Cell Immune Responses. <i>Advanced NanoBiomed Research</i> , 2022, 2, .	3.6	4
94	Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 362-368.	4.0	3
95	A tissue culture infectious dose-derived protocol for testing of SARS-CoV-2 neutralization of serum antibodies on adherent cells. <i>STAR Protocols</i> , 2021, 2, 100824.	1.2	3
96	Photochemically-Mediated Inflammation and Cross-Presentation of Mycobacterium bovis BCG Proteins Stimulates Strong CD4 and CD8 T-Cell Responses in Mice. <i>Frontiers in Immunology</i> , 2022, 13, 815609.	4.8	3
97	Multivalent paediatric allergy vaccines protect against allergic anaphylaxis in mice. <i>Clinical and Experimental Allergy</i> , 2014, 44, 429-437.	2.9	2
98	A critical appraisal of analyzing nasal provocation test results in allergen immunotherapy trials. <i>Rhinology</i> , 2014, 52, 137-141.	1.3	2
99	Abstract A008: Photochemical internalization: Light-induced enhancement of MHC Class I antigen presentation, giving strong enhancement of cytotoxic T-cell responses to vaccination. <i>Cancer Immunology Research</i> , 2016, 4, A008-A008.	3.4	1
100	Contents Vol. 141, 2006. <i>International Archives of Allergy and Immunology</i> , 2006, 141, 419-421.	2.1	0
101	A bizarre attack on the freedom of scientific expression. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1037-1038.	5.7	0
102	Safety and Satisfaction in High-Definition Power-Assisted Liposculpture in Men Under Local Anesthesia. <i>The American Journal of Cosmetic Surgery</i> , 0, , 074880682110247.	0.3	0
103	Editorial: Frontiersâ€™ Research Topic â€Cancer Vaccines: Time to Think Differently!â€ Frontiers in Immunology, 2021, 12, 771319.	4.8	0